Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

334.13
-14.6000-4.19%
Post-market: 334.130.00000.00%17:38 EDT
Volume:326.01K
Turnover:109.83M
Market Cap:7.42B
PE:-18.60
High:351.20
Open:350.00
Low:331.24
Close:348.73
Loading ...

TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
06 Mar

B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236

MT Newswires Live
·
28 Feb

Madrigal Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
28 Feb

Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

MT Newswires Live
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Madrigal Pharmaceuticals (MDGL) and Ligand Pharma (LGND)

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals Inc : B. Riley Raises to Buy From Neutral; Raises Target Price to $422 From $236

THOMSON REUTERS
·
27 Feb

Madrigal price target raised to $405 from $400 at H.C. Wainwright

TIPRANKS
·
27 Feb

High Growth Tech Stocks In US For February 2025

Simply Wall St.
·
27 Feb

Madrigal Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $405 From $400

THOMSON REUTERS
·
27 Feb

U.S. RESEARCH ROUNDUP-Abbvie, Freeport-McMoran, Goldman Sachs

Reuters
·
27 Feb

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com
·
27 Feb

Madrigal’s Financial Vulnerability: Overreliance on Specialty Pharmacies Threatens Revenue Stability

TIPRANKS
·
27 Feb

Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals Shares Jump After Q4 Beat, Release of New Data on Steatohepatitis Drug

MT Newswires Live
·
27 Feb

Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Zacks
·
27 Feb

Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS

TIPRANKS
·
27 Feb

BUZZ-Madrigal rises on robust sales and long-term data for liver disease drug

Reuters
·
26 Feb

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Motley Fool
·
26 Feb